Condition

Non-Muscle-Invasive Bladder Cancer (NMIBC) clinical trials and research

• 13Clinical trials
• 6Countries

Newest Non-Muscle-Invasive Bladder Cancer (NMIBC) clinical trials

All recruiting trials (13)

• Alpha1H before bladder tumor surgery in low/intermediate risk non-muscle-invasive bladder cancer

  This trial tests whether putting Alpha1H directly into the bladder before standard surgery helps prevent cancer from coming back or getting worse in adults with low- to intermediate-risk non-muscle-invasive bladder cancer.

  Recruiting Phase 3 Hamlet Pharma AB · Prague · NCT07804056

• Active surveillance versus single-dose intravesical chemo after TURBT in low-shedding intermediate-risk NMIBC

  This study tests whether some patients with intermediate-risk non-muscle-invasive bladder cancer can skip additional bladder chemotherapy after complete tumor removal if urine tests show a low-shedding profile.

  Recruiting at 5 sites Tianjin Medical University Second Hospital · Daqing and 4 other locations · NCT07749924

• LCS103 Herbal Formula for Preventing NMIBC Recurrence

  This study tests whether the LCS103 herbal formula added to standard care can help prevent bladder cancer recurrence in adults with non-muscle invasive bladder cancer.

  Recruiting LifeBiotic Medical Research Ltd. · Haifa · NCT07728474

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Disitamab Vedotin plus Mitomycin C for HER2-positive high-risk NMIBC

  This study tests whether giving disitamab vedotin through the bloodstream together with bladder-delivered mitomycin C can help people with HER2-expressing, high-risk non-muscle-invasive bladder cancer.

  Recruiting Phase 2 Shanxi Province Cancer Hospital · Taiyuan, Shanxi · NCT07646145

• Sexual health support after bladder cancer treatment

  This project will try sexological support to help adults about 12 months after bladder cancer treatment improve sexual function and intimacy.

  Recruiting University of Aarhus · Aarhus · NCT07339761

• Intravesical gemcitabine followed by docetaxel for high-grade BCG-unresponsive NMIBC

  This trial tests whether putting gemcitabine then docetaxel directly into the bladder can treat adults with high-grade non-muscle-invasive bladder cancer that did not respond to BCG.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT07322263

• Comparing bladder-sparing therapy versus bladder removal for recurrent high-grade NMIBC

  This project will test whether bladder-sparing treatments or bladder removal work better for adults with recurrent high-grade non-muscle-invasive bladder cancer by looking at costs, health outcomes, and patient and caregiver experiences.

  Recruiting at 6 sites University of Washington · Tampa, Florida and 5 other locations · NCT07225127

• Urine tumor DNA to reduce cystoscopy frequency for non‑muscle invasive bladder cancer

  This trial will test whether a urine tumor DNA (UroAmp) test can let people with non‑muscle invasive bladder cancer who finish induction therapy and have negative post‑treatment checks safely have fewer cystoscopies.

  Recruiting Lahey Clinic · Burlington, Massachusetts · NCT07187063

• Intravesical FL115 alone or with BCG for non‑muscle invasive bladder cancer

  This trial will try intravesical FL115, alone or combined with BCG, in adults with high‑grade, BCG‑unresponsive non‑muscle invasive bladder cancer to find safe dosing and see if it reduces recurrence.

  Recruiting at 12 sites Phase 1/2 Suzhou Forlong Biotechnology Co., Ltd · Beijing, Beijing Municipality and 11 other locations · NCT07122414

• Using mitomycin C before surgery to treat high-risk bladder cancer

  This study tests if giving mitomycin C before surgery can help people with high-risk bladder cancer stay cancer-free for a year compared to a placebo.

  Recruiting at 3 sites Phase 3 Tongji Hospital · Wuhan, Hubei and 2 other locations · NCT06696794

• Evaluating RAG-01 for patients with bladder cancer who didn't respond to BCG therapy

  This study is testing a new treatment called RAG-01 for people with bladder cancer who didn't get better after standard BCG therapy to see if it works and is safe.

  Recruiting at 3 sites Phase 1 Ractigen Therapeutics. · St Leonards, New South Wales and 2 other locations · NCT06351904

• Investigating SIM0237 for treating Non-Muscle-Invasive Bladder Cancer

  This study is testing a new treatment called SIM0237 for people with Non-Muscle-Invasive Bladder Cancer who haven't responded to standard therapy, to see if it is safe and effective.

  Recruiting at 5 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT06186414

Related topics

Quick answers

How many Non-Muscle-Invasive Bladder Cancer (NMIBC) clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in China (5 trials), United States (4 trials), Denmark (1 trial), Czechia (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 3: 2, Phase 2: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →